| Project/Area Number |
15K19360
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Cardiovascular medicine
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
Yaoita Nobuhiro 東北大学, 東北メディカル・メガバンク機構, 助教 (00735368)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 循環器・高血圧 / 肺高血圧症 / 血栓 / 線溶系 |
|---|
| Outline of Final Research Achievements |
The clot of chronic thromboembolic pulmonary hypertension (CTEPH) patients was more resistant to fibrinolysis than that of non-PH patients or pulmonary arterial hypertension (PAH)patients. The plasma levels of thrombin-activatable fibrinolysis inhibitor (TAFI) and the activation of TAFI were increased in CTEPH patients. Moreover, SNPs of cpb2, which induced the plasma levels of TAFI, was found in CTEPH patients. The impairment of fibrinolysis in CTEPH patients was inmproved with the inhibitor of avtivated TAFI.
In the TAFI overexpression mice, pulmonary hypertension was worse than wild type mice with hypoxic exposure and organaized thrombi ws found in pulmonary artery. Moreoover, TAFI increased the proliferation of smooth muscle cells of human.
These data suggest that TAFI could be a novel biomarker and realistic therapeutic target of CTEPH.
|
